STOCK TITAN
  1. Home
  2. News
  3. HLTH

Cue Health Inc. - HLTH STOCK NEWS

Welcome to our dedicated page for Cue Health news (Ticker: HLTH), a resource for investors and traders seeking the latest updates and insights on Cue Health stock.

Cue Health Inc. (HLTH) is a pioneering healthcare technology company that empowers individuals to manage their health with precision and convenience. Cue Health offers a revolutionary device that tracks key health and lifestyle indicators at the molecular level, including inflammation, vitamin D, fertility, influenza, and testosterone. This compact, user-friendly device enables consumers to perform these tests at home in just minutes.

The data collected by Cue is sent via Bluetooth 4.0 to the user’s smartphone, where the free Cue app provides an in-depth analysis of how activity, food, and sleep impact their health. By using noninvasive samples such as saliva, blood, or nasal swabs, users can access lab-quality information about their bodies on demand.

Recent Achievements:

  • The company has gained recognition for its innovative approach to personal health monitoring, making previously lab-exclusive data accessible to the general public.
  • Partnerships with leading healthcare providers have expanded the usability and integration of Cue devices.

Current Projects:

  • Continued development of advanced features within the Cue app, including interactive charts that help users visualize their health trends.
  • Research-based recommendations for foods proven to support optimal health tailored to the user's specific molecular data.

By offering a comprehensive tool for health management, Cue Health Inc. continues to play a significant role in transforming how individuals monitor and improve their well-being. The company’s dedication to providing accessible and real-time health data is a testament to its commitment to innovation and public health.

News

Concerned Stockholders of Cue Health Send Letter to Board

Rhea-AI Summary
Cue Health stockholders call for Board to cut expenditures and focus on core business
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
none
-
News

Peer-Reviewed Independent Study Published in Microbiology Spectrum Finds Cue Health’s Molecular COVID-19 Test is as Accurate as a Lab-Based PCR Test

Rhea-AI Summary
Cue Health's molecular COVID-19 test demonstrated 99.4% accuracy compared to lab-based PCR in a clinical study on asymptomatic people. The test provides fast results in 20 minutes and has 100% clinical sensitivity to detect positive cases. The study also showed high test sensitivity (98.7%) for detection at varying stages of infection and viral load. Cue's test offers critical benefits such as reducing the likelihood of spread, facilitating earlier access to treatment, and maintaining cost-effectiveness. Cue recently received FDA approval for its COVID-19 test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
covid-19
-
News

Cue Health Adopts Limited-Duration Shareholder Rights Plan

Rhea-AI Summary
Cue Health adopts shareholder rights plan to protect long-term value, responding to significant third-party share accumulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
none
News

Tarsadia Investments Sends Letter to Board of Cue Health, Inc.

Rhea-AI Summary
Tarsadia Investments calls on Cue Health board to take immediate action to prevent further destruction of stockholder value. They criticize Cue's flawed capital allocation and unsustainable cost structure. Urgent change is needed to address declining cash balance and destruction of stockholder value. Cue's stockholders have experienced a -97% decline in share price from IPO. Quarterly product revenues declined -97% from $223 million in Q3 2021 to $8 million in the past quarter. Cue may run out of cash and be required to raise $75 million in new equity, resulting in over 50% dilution to existing shareholders. Tarsadia submits Section 220 request to inspect company's books and records.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.45%
Tags
none
-
News

Cue Health to Present at Upcoming Investor Conferences

Rhea-AI Summary
Cue Health to present at investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.46%
Tags
conferences
-
News

Cue Health Reports Second Quarter 2023 Financial Results

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
earnings
News

Cue Health Awarded New $28 Million Federal Contract to Develop Flu A/B, RSV, COVID-19 Molecular Multiplex Test for Both Over-the-Counter and Point-of-Care Use

Rhea-AI Summary
Cue Health awarded $28 million contract to develop multiplex test for flu, RSV, and COVID-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.6%
Tags
covid-19
-
News

Cue Health to Announce Second Quarter 2023 Financial Results

Rhea-AI Summary
Cue Health Inc. (Nasdaq: HLTH) will release its second quarter 2023 financial results on August 9, 2023. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results and recent highlights. Participants can access the live call via telephone or the company's website. A replay of the webinar will be available on the website after the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
earnings
-
News

Cue Health Achieves Groundbreaking Milestone with FDA: First Company to Receive De Novo Authorization for a COVID-19 Home Use Test

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.86%
Tags
covid-19
News

Cue Health to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.17%
Tags
conferences

FAQ

What is the current stock price of Cue Health (HLTH)?

The current stock price of Cue Health (HLTH) is $0.0434 as of June 5, 2024.

What is the market cap of Cue Health (HLTH)?

The market cap of Cue Health (HLTH) is approximately 6.9M.

What does Cue Health Inc. specialize in?

Cue Health Inc. specializes in providing a device that tracks key health and lifestyle indicators at the molecular level, enabling at-home testing and real-time health data analysis.

How does Cue's device work?

The device uses noninvasive samples such as saliva, blood, or nasal swabs to measure health indicators and sends the data via Bluetooth to the user’s smartphone for analysis.

What health indicators can Cue track?

Cue can track inflammation, vitamin D, fertility, influenza, and testosterone levels in just minutes at home.

What is the Cue app?

The Cue app is a free application that receives data from the Cue device and provides detailed insights into how activity, food, and sleep affect your health.

What recent achievements has Cue Health made?

Cue Health has been recognized for making lab-quality health data accessible at home and has formed partnerships with leading healthcare providers to enhance device usability.

What are some current projects at Cue Health?

Current projects include developing advanced app features like interactive health charts and offering personalized, research-based health recommendations.

How does Cue Health send data to a user's smartphone?

Cue Health uses Bluetooth 4.0 technology to send health data from the device to the user's smartphone.

Can the Cue device track trends in personal health?

Yes, the Cue app provides interactive charts that allow users to monitor their health trends over time and discover new patterns.

Is Cue Health's testing method invasive?

No, Cue Health uses noninvasive methods such as saliva, blood, or nasal swabs to collect health data.

What makes Cue Health unique?

Cue Health is unique in its ability to provide immediate, lab-quality health data at home, enabling users to make informed health decisions in real-time.

Stock HLTH logo
Cue Health Inc.

Nasdaq:HLTH

HLTH Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

HLTH Stock Data

6.90M
159.09M
11.57%
52.81%
0.49%
Health Information Services
Laboratory Analytical Instruments
Link
United States of America
SAN DIEGO